Posters

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Sponsiello-Wang, Z.; Weitkunat, R.; Lee, P. N.
      Conference date
      Jun 24, 2008
      Conference name

      Society for Epidemiologic Research (SER) 2008
      Link to more information
      Topic
      Summary

      The present work reviews the available epidemiological data on the relationship of pancreatic cancer and smokeless tobacco used in North America and Europe. Meta-analytic methods were used to estimate the overall relative risk. Four cohort and seven case-control studies were identified. Two sets of estimates were selected for meta-analysis. The first meta-analysis was based on study-specific estimates for the overall population of smokers and nonsmokers combined, where they were available, otherwise on estimates for never smokers. The overall random-effects risk estimate was found to be 1.10 (95% confidence interval 0.73-1.65). Sub-group analyses by continent, study type, or type of smokeless tobacco also showed no increased risk. The second meta-analysis was based on study-specific estimates for never smokers, where they were available, otherwise on combined smokers/nonsmokers estimates. The overall random-effects risk estimate was found to be 1.15 (95% confidence interval 0.67-1.98). There were, however, some indications of increased risk in cohort studies, in studies conducted in Sweden or Norway, and in studies of snuff. As there are a number of weaknesses in the currently available studies, no definite conclusion can be drawn. Our results are less indicative of a causal relationship than other reviewers have suggested; additional studies will have to be conducted to clarify the situation.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.